Equitec Proprietary Markets’s Esperion Therapeutics ESPR Stock Holding History

Equitec Proprietary Markets’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.09M	Buy	+345,800	New	+$967K	0.2%	29
2018 Q2	–	Sell	-1,500	Closed	-$108K	–	66
2018 Q1	$108K	Buy	+1,500	New	+$110K	0.03%	47
2017 Q4	–	Sell	-400	Closed	-$21.5K	–	83
2017 Q3	$20K	Sell	400 -18	-4%	-$868	﹤0.01%	84
2017 Q2	$19K	Sell	418 -52,175	-99%	-$1.92M	﹤0.01%	99
2017 Q1	$1.86M	Buy	52,593 +50,659	+2,619%	+$1.16M	0.11%	37
2016 Q4	$24K	Buy	1,934 +1,334	+222%	+$15.9K	﹤0.01%	115
2016 Q3	$8K	Buy	600 +300	+100%	+$3.4K	﹤0.01%	130
2016 Q2	$3K	Sell	300 -1,000	-77%	-$16.6K	﹤0.01%	142
2016 Q1	$22K	Buy	1,300 +339	+35%	+$5.45K	﹤0.01%	128
2015 Q4	$21K	Buy	961 +461	+92%	+$11.6K	﹤0.01%	134
2015 Q3	$12K	Buy	+500	New	+$31.4K	﹤0.01%	157

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Equitec Proprietary Markets's ESPR Position: Q2 2026 in Review

Equitec Proprietary Markets opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 345,800 shares worth $1.09M. The stake represents 0.2% of the portfolio and ranks #29 among its holdings. This is a return to the name: Equitec Proprietary Markets previously reported a position in ESPR as recently as Q1 2018.

Equitec Proprietary Markets first reported a position in ESPR in Q3 2015 and has held it in 11 quarters since. The position peaked at $1.86M in Q1 2017. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Equitec Proprietary Markets held 345,800 shares of Esperion Therapeutics worth $1.09M as of Q2 2026.
Esperion Therapeutics was a new Equitec Proprietary Markets position in Q2 2026.
Esperion Therapeutics made up 0.2% of Equitec Proprietary Markets's portfolio in Q2 2026, its #29 holding.
Equitec Proprietary Markets first reported a position in Esperion Therapeutics in Q3 2015 and has held it in 11 quarters since.
Equitec Proprietary Markets's Esperion Therapeutics position peaked at $1.86M in Q1 2017.
192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Equitec Proprietary Markets's 13F filing for Q2 2026, filed 20 Jul 2026.